
Comparing Single-Inhaler Therapy to Traditional Triple Therapies in Adults with Uncontrolled Asthma: A Comprehensive Meta-Analysis
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.

Metformin and Mediterranean Diet: A Strategy for Preventing Diabetes in Metabolic Syndrome
The MeMeMe randomized trial studied whether metformin (1,700 mg/day), with or without a Mediterranean diet (MedDiet), could reduce the incidence of major noncommunicable diseases (NCDs) in individuals with metabolic syndrome (MetS). The trial included 1,442 participants, randomly assigned to one of four groups: metformin alone, metformin + MedDiet, placebo alone, or placebo + MedDiet. The participants were followed for an average of three years, with the primary outcome being the cumulative incidence of type 2 diabetes, cardiovascular diseases, and cancer.

FDA Grants Significant Approval to Vertex Pharmaceuticals
Vertex Pharmaceuticals has recently achieved two significant FDA approvals in just 41 days. On December 20, 2024, the FDA approved Alyftrek for treating cystic fibrosis (CF), followed by the approval of Journavx, a novel treatment for moderate-to-severe acute pain, just a few days later.